ATE308344T1 - Auf peptiden basierende tragvorrichtungen für sternzellen - Google Patents
Auf peptiden basierende tragvorrichtungen für sternzellenInfo
- Publication number
- ATE308344T1 ATE308344T1 AT98949252T AT98949252T ATE308344T1 AT E308344 T1 ATE308344 T1 AT E308344T1 AT 98949252 T AT98949252 T AT 98949252T AT 98949252 T AT98949252 T AT 98949252T AT E308344 T1 ATE308344 T1 AT E308344T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor
- disease
- peptide
- hsc
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL1998/000579 WO2000023113A1 (en) | 1998-10-08 | 1998-10-08 | Peptide-based carrier devices for stellate cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE308344T1 true ATE308344T1 (de) | 2005-11-15 |
Family
ID=19866457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98949252T ATE308344T1 (de) | 1998-10-08 | 1998-10-08 | Auf peptiden basierende tragvorrichtungen für sternzellen |
Country Status (9)
Country | Link |
---|---|
US (3) | US6844319B1 (de) |
EP (1) | EP1117443B1 (de) |
JP (1) | JP2002532384A (de) |
AT (1) | ATE308344T1 (de) |
AU (2) | AU770340B2 (de) |
CA (1) | CA2345932C (de) |
DE (1) | DE69832204T2 (de) |
HK (1) | HK1039450B (de) |
WO (1) | WO2000023113A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264949B1 (en) | 1998-09-29 | 2001-07-24 | Mount Sinai School Of Medicine Of New York University | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis |
WO2003035083A1 (de) * | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz |
US7160577B2 (en) * | 2002-05-02 | 2007-01-09 | Micron Technology, Inc. | Methods for atomic-layer deposition of aluminum oxides in integrated circuits |
US7589029B2 (en) * | 2002-05-02 | 2009-09-15 | Micron Technology, Inc. | Atomic layer deposition and conversion |
US20070299029A1 (en) * | 2005-06-09 | 2007-12-27 | Agency For Science, Technology And Research | Hepatic stellate cell specific promoter and uses thereof |
US7863251B2 (en) * | 2005-06-09 | 2011-01-04 | Agency For Science, Technology And Research | Hepatic stellate cell specific promoter and uses thereof |
US7927948B2 (en) | 2005-07-20 | 2011-04-19 | Micron Technology, Inc. | Devices with nanocrystals and methods of formation |
US7989290B2 (en) | 2005-08-04 | 2011-08-02 | Micron Technology, Inc. | Methods for forming rhodium-based charge traps and apparatus including rhodium-based charge traps |
US7575978B2 (en) | 2005-08-04 | 2009-08-18 | Micron Technology, Inc. | Method for making conductive nanoparticle charge storage element |
WO2007038568A1 (en) * | 2005-09-27 | 2007-04-05 | Teotten Diagnostics, Inc. | Methods for detection of fungal disease |
GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
US8367506B2 (en) | 2007-06-04 | 2013-02-05 | Micron Technology, Inc. | High-k dielectrics with gold nano-particles |
EP2448600B1 (de) * | 2009-07-03 | 2016-03-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Auf den kationunabhängigen mannose 6-phosphat-rezeptor gerichtete verbindungen |
EP2343081A1 (de) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon-Analoga |
WO2012173994A2 (en) | 2011-06-15 | 2012-12-20 | Dicerna Pharmaceuticals, Inc. | Phase changing formulations of nucleic acid payloads |
JP5378469B2 (ja) | 2011-08-11 | 2013-12-25 | 学校法人 日本歯科大学 | 医療用薬剤 |
JP2022513299A (ja) | 2018-12-19 | 2022-02-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0906015A4 (de) | 1996-06-06 | 2004-05-12 | Neorx Corp | Mittel zur unterdrückung von rückhalteprozessen in der leber |
US5939383A (en) * | 1996-11-15 | 1999-08-17 | Remacle; Jose | Cyclic peptides bearing a tail designed for subsequent chemical coupling and process for preparing same |
-
1998
- 1998-10-08 JP JP2000576886A patent/JP2002532384A/ja active Pending
- 1998-10-08 US US09/806,837 patent/US6844319B1/en not_active Expired - Fee Related
- 1998-10-08 WO PCT/NL1998/000579 patent/WO2000023113A1/en active IP Right Grant
- 1998-10-08 AT AT98949252T patent/ATE308344T1/de not_active IP Right Cessation
- 1998-10-08 DE DE69832204T patent/DE69832204T2/de not_active Expired - Lifetime
- 1998-10-08 EP EP98949252A patent/EP1117443B1/de not_active Expired - Lifetime
- 1998-10-08 AU AU95609/98A patent/AU770340B2/en not_active Ceased
- 1998-10-08 CA CA2345932A patent/CA2345932C/en not_active Expired - Fee Related
-
2002
- 2002-01-25 HK HK02100574.2A patent/HK1039450B/zh not_active IP Right Cessation
-
2004
- 2004-12-15 US US11/012,056 patent/US7348313B2/en not_active Expired - Fee Related
-
2005
- 2005-08-15 AU AU2005203633A patent/AU2005203633B2/en not_active Ceased
-
2008
- 2008-03-24 US US12/076,802 patent/US20080267877A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002532384A (ja) | 2002-10-02 |
AU2005203633B2 (en) | 2007-09-06 |
US20080267877A1 (en) | 2008-10-30 |
DE69832204D1 (de) | 2005-12-08 |
US6844319B1 (en) | 2005-01-18 |
AU2005203633A1 (en) | 2005-09-08 |
US20050227916A1 (en) | 2005-10-13 |
DE69832204T2 (de) | 2006-07-27 |
AU9560998A (en) | 2000-05-08 |
HK1039450B (zh) | 2006-02-03 |
US7348313B2 (en) | 2008-03-25 |
HK1039450A1 (en) | 2002-04-26 |
AU770340B2 (en) | 2004-02-19 |
EP1117443A1 (de) | 2001-07-25 |
CA2345932A1 (en) | 2000-04-27 |
CA2345932C (en) | 2010-07-13 |
WO2000023113A1 (en) | 2000-04-27 |
EP1117443B1 (de) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE308344T1 (de) | Auf peptiden basierende tragvorrichtungen für sternzellen | |
Brown et al. | Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections | |
EA201170337A1 (ru) | Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения | |
EA200000629A1 (ru) | Стабилизированные растворы терипаратида | |
Velkov et al. | Rediscovering the octapeptins | |
ATE384534T1 (de) | Lösung zur nagel-verwendung | |
Yoshikawa et al. | Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4–FC131 interactions | |
DK0528312T3 (da) | Cykliske peptider og anvendelse deraf | |
EA200901108A1 (ru) | Соагонисты глюкагоновых/glp-1-рецепторов | |
HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
ATE318598T1 (de) | Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen | |
CA2097192A1 (en) | Bombesin antagonists | |
WO1999060013A3 (en) | Il-6 antagonist peptides | |
Tamamura et al. | Structure–activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds | |
DE69927582D1 (de) | Neue analoga von 16-hydroxyeicosatetraensäure | |
CA2182795A1 (en) | Superactive vip antagonists | |
EP1571155A4 (de) | Peptide und medizinische zusammensetzungen mit denselben | |
RU2015108678A (ru) | Составы ангиотензина для перорального применения | |
Saitoh et al. | Restricted intestinal absorption of some β-lactam antibiotics by an energy-dependent efflux system in rat intestine | |
Tamamura et al. | Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs | |
AR030247A1 (es) | Arileteno-sulfonamidas, composiciones farmaceuticas , procedimiento para su produccion y el uso de las mismas para la produccion de composiciones farmaceuticas | |
ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
ITRM20020277A1 (it) | Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni. | |
WO2001034640A3 (de) | Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung | |
AR022537A1 (es) | Composiciones farmaceuticas que comprenden sales de peptidos farmaceuticamente activos de liberacion sostenida; y metodo para preparar dichas composiciones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |